Blood brain barrier permeability may have limited the efficacy of cediranib and bevacizumab would a priori only be able to scavenge humoral VEGF, but probably not be able to prevent autocrine signaling that is likely to be relevant in glioblastoma, too [30]. The gene discussed is VEGFA; the disease is glioblastoma.